Erasca (ERAS) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic focus and pipeline overview

• Focused on RAS-MAPK pathway with two lead programs: ERAS-15 (pan-RAS) and ERAS-4001 (pan-KRAS), both targeting solid tumors.

• ERAS-15 and ERAS-4001 exhibit strong preclinical activity, high oral bioavailability, and robust intellectual property protection through 2043.

• ERAS-15 demonstrates high potency, requiring one-tenth the dose of a key competitor to achieve similar tumor regression in preclinical models.

• ERAS-4001 shows potent inhibition across KRAS mutations and wild-type, with promising PK and a potential wide therapeutic window.

• Both programs are supported by a strong scientific advisory board and significant cash runway into the second half of 2028.

Clinical development and early data

• AURORAS-1 (ERAS-15) first-in-human trial is enrolling briskly, targeting patients with advanced RAS mutations and no prior RAS inhibitor treatment.

• Early clinical data for ERAS-15 show confirmed and unconfirmed partial responses at low doses, with all responding patients remaining on treatment at data cutoff.

• Safety and tolerability profile for ERAS-15 is favorable, with no dose-limiting toxicities and predominantly low-grade adverse events.

• Top-line safety, PK, and efficacy data for dozens of patients are expected in the first half of the year, with expansion and combination cohorts planned for the second half.

• ERAS-4001 is enrolling in the BOREALIS-1 trial, with phase 1 monotherapy data expected in the second half of the year.

Differentiation, competitive landscape, and future plans

• ERAS-15’s high binding affinity to CyPA leads to superior tumor distribution, longer residence time, and enhanced potency compared to competitors.

• Early clinical responses at much lower doses than competitors suggest potential best-in-class status for ERAS-15.

• No numerical ORR threshold is set; focus is on the totality of safety, tolerability, PK, and efficacy data.

• Commercial strategy considers both best-in-class and second-in-class scenarios, with significant unmet need supporting multiple entrants.

• Combination strategies for both molecules will be data-driven, with potential for use alongside standard of care and investigational agents.